News

High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.

New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.

Investigators added improvements were needed regarding access to complete diagnostic evaluation among Black patients, citing disparities in care.

Data show the majority of patients who initiated crizanlizumab remained on therapy, while a third of patients saw barriers including insurance coverage.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

New cohort analysis suggest a heightened risk of atrial fibrillation may be worsening patients' life expectancies.

Investigators aimed to improve lentiviral vectors to boost therapeutic β-like globin levels without increasing the mutagenic vector load in hematopoietic stem/progenitor cells.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.

Moderate weekly consumption of beer was marginally associated with a reduction in the risk of Crohn’s disease.

New data for the Rocket Pharmaceutical gene therapy candidate show durable benefit in patients 6 months out from transplant.

The global biopharmaceutical company released research data on rozanolixizumab and zilucoplan at the 2021 ASH annual meeting and exposition.

An international assessment shows many patients are wary of emergency rooms, and clinicians want more diverse therapies.

Data show 12 of 25 strokes (48%) in a cohort of children did not met the definition of typical stroke related to sickle cell cerebral vasculopathy.

Data from phase 1 and phase 2 of the Alta study was presented at ASH this weekend.

Defined roles and research-informed recommendations are lacking for clinicians navigating birth control with females with sickle cell.

Investigators suggested this approach will allow for comprehensive mapping of the genomic landscape and clonal evolution of stem cells in sickle cell patients

Patients with sickle cell disease often suffer from acute kidney injuries and chronic kidney disease.

Shaji Kumar, MD, presents final Phase 3 data of the BELLINI trial at the ASH 2021 conference.

An ongoing assessment of caregivers considering hydroxyurea initiation for children with sickle cell disease provides a look into how such families are handling telemedicine and the pandemic.

Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.

New ASH 2021 data shows how guidance is still lacking for clinicians responsible for addressing contraception with women with sickle cell disease.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

Though seasonal flu activity has remained low, the number of influenza virus detections reported by clinical and public health laboratories had increased in recent weeks.

New data from the CDC highlights the need to mitigate the potential severity of the influenza season, particularly with COVID-19's substantial impact on care systems.

Prior to the study, little was known on the relationship between the disease and fractures.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

The data shows booster shots offer particularly strong protection against the variant.